Rational Design of a Glycoconjugate Vaccine against Group A <i>Streptococcus</i>

Rational Design of a Glycoconjugate Vaccine against Group A <i>Streptococcus</i>

No commercial vaccine is yet available against Group A <i>Streptococcus</i> (GAS), major cause of pharyngitis and impetigo, with a high frequency of serious sequelae in low- and middle-income countries. Group A Carbohydrate (GAC), conjugated to an appropriate carrier protein, has been pr...

Full description

Bibliographic Details
Main Authors: Roberta Di Benedetto, Francesca Mancini, Martina Carducci, Gianmarco Gasperini, Danilo Gomes Moriel, Allan Saul, Francesca Necchi, Rino Rappuoli, Francesca Micoli
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:International Journal of Molecular Sciences
Subjects:
Group A <i>Streptococcus</i>
Group A Carbohydrate
glycoconjugate
vaccine
SLO
SpyCEP
Online Access:https://www.mdpi.com/1422-0067/21/22/8558

Internet

https://www.mdpi.com/1422-0067/21/22/8558

Similar Items